VEGF-C gene therapy (Herantis Pharma)

N/A

Report date: 2023/10/26 16:04:25

Base Information

Drug NameVEGF-C gene therapy (Herantis Pharma)
Drug Alias NameAd-VEGF-C - Herantis PharmaLymfactinLX-1101Ad-VEGF-C
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionVascular endothelial growth factor C gene transference
TargetsVascular endothelial growth factor C
Therapy Area/IndicationsLymphedema
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenFinland
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHerantis Pharma
China Registration ClassN/A

Develop Information

Active CompaniesHerantis Pharma Plc.
Inactive CompaniesN/A
Active IndicationsLymphedema
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A